{"DataElement":{"publicId":"6588318","version":"1","preferredName":"Intrahepatic Bile Duct Cancer AJCC Edition 8 Group Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for intrahepatic bile duct carcinoma, using AJCC Ed. 8 criteria.","longName":"IBD_AJC8_DZ_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6587419","version":"1","preferredName":"Intrahepatic Bile Duct Neoplasm Pathologic Stage Grouping","preferredDefinition":"The bile ducts which are located within the liver. They include the small interlobular bile ducts, intrahepatic large bile ducts, and the intrahepatic portions of the left and right hepatic ducts._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Caused by or altered by or manifesting disease or pathology._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"6587405v1.0:2230144v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6587405","version":"1","preferredName":"Intrahepatic Bile Duct Neoplasm","preferredDefinition":"The bile ducts which are located within the liver. They include the small interlobular bile ducts, intrahepatic large bile ducts, and the intrahepatic portions of the left and right hepatic ducts.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C12677:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrahepatic Bile Duct","conceptCode":"C12677","definition":"The bile ducts which are located within the liver. They include the small interlobular bile ducts, intrahepatic large bile ducts, and the intrahepatic portions of the left and right hepatic ducts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD295D1-E8A8-06EC-E053-F662850A3CC8","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230144","version":"1","preferredName":"Pathologic Stage Grouping","preferredDefinition":"Pathologic; caused by or altered by or manifesting disease or pathology.:Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C25610:C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CCE-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7CD2BDA7-4B9B-06E8-E053-F662850AB219","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-30-19 tmt released.; 12/12/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6587555","version":"1","preferredName":"Intrahepatic Bile Duct Carcinoma American Joint Committee on Cancer Edition 8 Group Stage","preferredDefinition":"A finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas (mixed hepatocholangiocarcinomas), and primary neuroendocrine tumors of the liver. Primary sarcomas of the liver, pure hepatocellular carcinomas, hilar cholangiocarcinomas, and gallbladder carcinomas are not staged using this staging system. (from AJCC 8th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6587555v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IV","valueDescription":"Stage IV Intrahepatic Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587557","version":"1","preferredName":"Stage IV Intrahepatic Bile Duct Cancer AJCC v8","longName":"6587557","preferredDefinition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IV Intrahepatic Bile Duct Cancer AJCC v8","conceptCode":"C134619","definition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD4D5B3-9DAE-7238-E053-F662850A34EF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD4D5B3-9DC7-7238-E053-F662850A34EF","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587559","version":"1","preferredName":"Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8","longName":"6587559","preferredDefinition":"Stage IIIB includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8","conceptCode":"C134618","definition":"Stage IIIB includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD4D5B3-9DD4-7238-E053-F662850A34EF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD4D5B3-9DED-7238-E053-F662850A34EF","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587561","version":"1","preferredName":"Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8","longName":"6587561","preferredDefinition":"Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8","conceptCode":"C134616","definition":"Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD4D5B3-9DFA-7238-E053-F662850A34EF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD4D5B3-9E13-7238-E053-F662850A34EF","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Intrahepatic Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587563","version":"1","preferredName":"Stage II Intrahepatic Bile Duct Cancer AJCC v8","longName":"6587563","preferredDefinition":"Stage II includes: T2, N0, M0. T2: Solitary tumor with intrahepatic vascular invasion, or multiple tumors, with or without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Intrahepatic Bile Duct Cancer AJCC v8","conceptCode":"C134614","definition":"Stage II includes: T2, N0, M0. T2: Solitary tumor with intrahepatic vascular invasion, or multiple tumors, with or without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD4D5B3-9E20-7238-E053-F662850A34EF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD4D5B3-9E39-7238-E053-F662850A34EF","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IB","valueDescription":"Stage IB Intrahepatic Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587565","version":"1","preferredName":"Stage IB Intrahepatic Bile Duct Cancer AJCC v8","longName":"6587565","preferredDefinition":"Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB Intrahepatic Bile Duct Cancer AJCC v8","conceptCode":"C134612","definition":"Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD4D5B3-9E46-7238-E053-F662850A34EF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD4D5B3-9E5F-7238-E053-F662850A34EF","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IA","valueDescription":"Stage IA Intrahepatic Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587567","version":"1","preferredName":"Stage IA Intrahepatic Bile Duct Cancer AJCC v8","longName":"6587567","preferredDefinition":"Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal to or less than 5 cm without vascular invasion.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA Intrahepatic Bile Duct Cancer AJCC v8","conceptCode":"C134611","definition":"Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal to or less than 5 cm without vascular invasion.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD4D5B3-9E6C-7238-E053-F662850A34EF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD4D5B3-9E85-7238-E053-F662850A34EF","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"0","valueDescription":"Stage 0 Intrahepatic Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587569","version":"1","preferredName":"Stage 0 Intrahepatic Bile Duct Cancer AJCC v8","longName":"6587569","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intraductal tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Intrahepatic Bile Duct Cancer AJCC v8","conceptCode":"C134609","definition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intraductal tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD4D5B3-9E92-7238-E053-F662850A34EF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD4D5B3-9EAB-7238-E053-F662850A34EF","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6587554","version":"1","preferredName":"Intrahepatic Bile Duct Cancer TNM Finding v8 American Joint Committee on Cancer Stage Grouping Stage","preferredDefinition":"A finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas (mixed hepatocholangiocarcinomas), and primary neuroendocrine tumors of the liver. Primary sarcomas of the liver, pure hepatocellular carcinomas, hilar cholangiocarcinomas, and gallbladder carcinomas are not staged using this staging system. (from AJCC 8th Ed.):A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C134577:C39315:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrahepatic Bile Duct Cancer TNM Finding v8","conceptCode":"C134577","definition":"A finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas (mixed hepatocholangiocarcinomas), and primary neuroendocrine tumors of the liver. Primary sarcomas of the liver, pure hepatocellular carcinomas, hilar cholangiocarcinomas, and gallbladder carcinomas are not staged using this staging system. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD4D5B3-9D81-7238-E053-F662850A34EF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7CD4D5B3-9D92-7238-E053-F662850A34EF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-20-19 released per MC.; 12/12/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6581918","version":"1","longName":"Bile Duct(s)","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Disease stage","type":"Preferred Question Text","description":"Disease stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7CE6122C-79FB-5985-E053-F662850A265C","latestVersionIndicator":"Yes","beginDate":"2018-12-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-13","modifiedBy":"KNABLEJ","dateModified":"2020-02-24","changeDescription":"2/24/20 jk removed CPTAC CSI.  8-30-19 TMT released per MC.; 12/13/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}